ClinicalTrials.gg
CompletedNCT02273050Updated Feb 5, 2018Results posted

Evaluate the Efficacy and Safety of Saxagliptin in Combination With Metformin IR Compared to Saxagliptin Monotherapy and to Metformin IR Monotherapy in Drug Naive Chinese Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control

A Phase 3 interventional study of Saxagliptin 5 mg and Placebo 5 mg for Saxagliptin in Type 2 Diabetes Mellitus, sponsored by AstraZeneca. Completed at 17 sites in China. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2018-02-05.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,136
Allocation
Randomized
Ages
18 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 74 studies testing saxagliptin in Diabetes Mellitus, Type 2 — 1 open to participants now, 1 under way, none of them phase 3. saxagliptin · Diabetes Mellitus, Type 2.

Enrollment
5th of 74
1,136 · median 138
Started
2014
with 9 others
Phase 3
27 of 74
none open now
Registered
54th of 74
by date
Lead sponsor
48 of 74
AstraZeneca

Among the 74 studies testing saxagliptin in Diabetes Mellitus, Type 2, this one is the 5th largest by enrollment, is one of 10 that started in 2014, is one of 27 in phase 3, and was the 54th registered.

Diabetes Mellitus, Type 2

10,396 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

1 of the 74 studies testing saxagliptin in Diabetes Mellitus, Type 2 is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About saxagliptin

saxagliptin: first FDA approval 2009 (ONGLYZA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 18 Years to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 74 studies testing saxagliptin in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

A Multicenter, Randomized, Double-Blind, Active-Controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Saxagliptin in Combination with Metformin IR as Initial Therapy Compared to Saxagliptin Monotherapy and to Metformin IR Monotherapy in Subjects with Type 2 Diabetes who have Inadequate Glycaemic Control

Read the detailed description

Allocation: Randomized Endpoint Classification: Efficacy/Safety study Intervention Model: Parallel Assignment Masking: Double Blind Primary Purpose: Treatment

03

Conditions studied

  • Type 2 Diabetes Mellitus

Keywords

  • Type 2 Diabetes Mellitus, Dipeptidyl-Peptidase 4 Inhibitors, Saxagliptin, Metformin, Endocrine System Diseases
04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects with type 2 diabetes mellitus; 2. ≥8% but ≤12%; 3.Fasting C-peptide ≥1.0 ng/ml; 4. Subject will be drug naïve; 5. ≤40 kg/m2.

Exclusion criteria

Exclusion Criteria:

  1. Symptoms of poorly controlled diabetes; 2. Chronic or repeated intermittent treatment ; 3. Calculated \<60 ml/min or serum creatinine >132.6 μmol/L (>1.5 mg/dL) for men, >123.8 μmol/L (>1.4 mg/dL) for women; 4. Creatine Kinase ≥3x ; 5.Abnormal TSH value at screening will be further evaluated by free T4, subjects with an abnormal free T4 will be excluded; 6. History of administration of any antihyperglycaemic therapy for a total of 28 days or for more than three consecutive days or a total of seven non-consecutive days during the eight weeks prior to screening; 7. Current treatment with a strong /5 inhibitor; 8. Prior treatment with saxagliptin or any DPP-4 inhibitor; 9. Significant or history of cardiovascular disease, renal disease, psychiatric disorders, individuals, hemoglobinopathies, liver disease, Pancreatitis.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,136 participants (actual)

Study arms

  • Experimental
    Saxagliptin 5 mg + Metformin (500 mg with titration)

    Saxagliptin 5 mg once daily and metformin 500 mg once daily, then titrate. Acarbose will be used as rescue medication as needed.

    Drug: Saxagliptin 5 mg · Drug: Metformin 500 mg with titration

  • Active comparator
    Saxagliptin 5 mg + Placebo

    Saxagliptin 5 mg once daily and Placebo 500 mg once daily, then titrate. Acarbose will be used as rescue medication as needed.

    Drug: Saxagliptin 5 mg · Drug: Placebo 500 mg for metformin (with titration)

  • Active comparator
    Metformin (500 mg with titration) + Placebo

    Placebo 5 mg once daily and metformin 500 mg once daily, then titrate. Acarbose will be used as rescue medication as needed.

    Drug: Placebo 5 mg for Saxagliptin · Drug: Metformin 500 mg with titration

Interventions

  • Tablet, Oral, 5 mg, Once daily in the morning

    Also known as: Onglyza, BMS-477118

  • DrugPlacebo 5 mg for Saxagliptin

    Tablet, Oral, 5 mg, Once daily in the morning

  • DrugPlacebo 500 mg for metformin (with titration)

    Tablet, 500 mg, Once daily in the evening the first two weeks and thereafter according to titration.

  • DrugMetformin 500 mg with titration

    Drug page: Metformin

    Tablet, 500 mg, Once daily in the evening the first two weeks and thereafter according to titration.

    Also known as: Glucophage

06

What researchers measure

Primary outcomes

  1. Change From Baseline in HbA1c From Baseline to Week 24 Provided That it is Prior to Rescue

    To evaluate the efficacy of the combination therapy (saxagliptin + metformin) when compared to placebo + metformin and placebo + saxagliptin with respect to reduction in HbA1c (%) at the end of 24 weeks of double-blinded treatment.

    Time frame: Baseline to Week 24 (prior to rescue)

Secondary outcomes

  1. Glycemic Response Defined as HbA1c < 7.0% at Week 24

    To evaluate the efficacy of the combination therapy (saxagliptin + metformin) when compared to placebo + metformin and placebo + saxagliptin with respect to the proportion of subjects achieving a therapeutic glycemic response defined as HbA1c \< 7.0% at the end of 24 weeks of double-blinded treatment.

    Time frame: Week 24 (prior to rescue)

  2. Change From Baseline to Week 24 (Prior to Rescue) in Fasting Plasma Glucose

    To evaluate the efficacy of the combination therapy (saxagliptin + metformin) when compared to placebo + metformin and placebo + saxagliptin with respect to reduction in fasting plasma glucose at the end of 24 weeks of double-blinded treatment.

    Time frame: Baseline to Week 24 prior to rescue

  3. Change From Baseline to Week 24 (Prior to Rescue) in Area Under the Curve From 0-180 Minutes for Postprandial Glucose Response to a Meal Tolerance Test

    To evaluate the efficacy of the combination therapy (saxagliptin + metformin) when compared to placebo + metformin and placebo + saxagliptin with respect to change in 180-minute postprandial glucose response to a meal tolerance test at the end of 24 weeks of double-blinded treatment.

    Time frame: Baseline to Week 24 prior to rescue

  4. Glycemic Response Defined as HbA1c ≤ 6.5% at Week 24

    To evaluate the efficacy of the combination therapy (saxagliptin + metformin) when compared to placebo + metformin and placebo + saxagliptin with respect to the proportion of subjects achieving a therapeutic glycemic response defined as HbA1c ≤ 6.5% at the end of 24 weeks of double-blinded treatment.

    Time frame: Week 24 (prior to rescue)

  5. Change From Baseline to Week 24 in 120-minute Postprandial Glucose Response to a Meal Tolerance Test

    To evaluate the efficacy of the combination therapy (saxagliptin + metformin) when compared to placebo + metformin and placebo + saxagliptin with respect to change in 120-minute postprandial glucose response to a meal tolerance test at the end of 24 weeks of double-blinded treatment.

    Time frame: Baseline to Week 24 prior to rescue

  6. Patients Rescued for Failing to Achieve Pre-specified Glycemic Targets or Discontinuation for Lack of Efficacy During the 24-week Double-blind Treatment Phase

    To evaluate the efficacy of the combination therapy (saxagliptin + metformin) when compared to placebo + metformin and placebo + saxagliptin with respect to the proportion of subjects requiring rescue for failing to achieve pre-specified glycemic targets or discontinuing for lack of efficacy within the 24 weeks of double-blinded treatment.

    Time frame: Baseline to Week 24

07

Results

Posted Feb 5, 2018

Participant flow

The study was conducted in 25 centers between 18 December 2014 and 03 August 2016.

Participant flow — Overall Study
MilestoneMETFORMIN + PLACEBO 5MG QDSAXAGLIPTIN 5MG QD + METFORMINSAXAGLIPTIN 5MG QD + PLACEBO
Started210216214
Completed186194185
Not completed242229
Withdrew: Adverse event433
Withdrew: Death001
Withdrew: Dev. of study spec. withdrawal criteria011
Withdrew: Lack of efficacy011
Withdrew: Withdrawal by subject171416
Withdrew: Lost to follow-up023
Withdrew: Protocol violation314

Outcome measures

PrimaryChange From Baseline in HbA1c From Baseline to Week 24 Provided That it is Prior to Rescue

To evaluate the efficacy of the combination therapy (saxagliptin + metformin) when compared to placebo + metformin and placebo + saxagliptin with respect to reduction in HbA1c (%) at the end of 24 weeks of double-blinded treatment.

Time frame:
Baseline to Week 24 (prior to rescue)
Reported as:
Least squares mean · % HbA1c
Change From Baseline in HbA1c From Baseline to Week 24 Provided That it is Prior to Rescue
% HbA1cSaxagliptin + MetforminSaxagliptin + PlaceboMetformin + Placebo
Change From Baseline in HbA1c From Baseline to Week 24 Provided That it is Prior to Rescue-3.007 ± 0.0706-2.123 ± 0.0701-2.794 ± 0.0715
Statistical analysis
  • Saxagliptin + Metformin vs Saxagliptin + Placebo · ANCOVA · p = <0.001 · Mean difference (net): -0.885 · 95% CI -1.080 to -0.689
  • Saxagliptin + Metformin vs Metformin + Placebo · ANCOVA · p = 0.034 · Mean difference (net): -0.213 · 95% CI -0.410 to -0.016
SecondaryGlycemic Response Defined as HbA1c < 7.0% at Week 24

To evaluate the efficacy of the combination therapy (saxagliptin + metformin) when compared to placebo + metformin and placebo + saxagliptin with respect to the proportion of subjects achieving a therapeutic glycemic response defined as HbA1c \< 7.0% at the end of 24 weeks of double-blinded treatment.

Time frame:
Week 24 (prior to rescue)
Reported as:
Number · Percentage of patients
Glycemic Response Defined as HbA1c < 7.0% at Week 24
Percentage of patientsSaxagliptin + MetforminSaxagliptin + PlaceboMetformin + Placebo
Glycemic Response Defined as HbA1c < 7.0% at Week 2481.844.371.1
Statistical analysis
  • Saxagliptin + Metformin vs Saxagliptin + Placebo · Fisher Exact · p = <0.001 · Mean difference (net): 37.5 · 95% CI 29.0 to 46.0
  • Saxagliptin + Metformin vs Metformin + Placebo · Fisher Exact · p = 0.011 · Mean difference (net): 10.7 · 95% CI 2.6 to 18.9
SecondaryChange From Baseline to Week 24 (Prior to Rescue) in Fasting Plasma Glucose

To evaluate the efficacy of the combination therapy (saxagliptin + metformin) when compared to placebo + metformin and placebo + saxagliptin with respect to reduction in fasting plasma glucose at the end of 24 weeks of double-blinded treatment.

Time frame:
Baseline to Week 24 prior to rescue
Reported as:
Least squares mean · mmol/L
Change From Baseline to Week 24 (Prior to Rescue) in Fasting Plasma Glucose
mmol/LSaxagliptin + MetforminSaxagliptin + PlaceboMetformin + Placebo
Change From Baseline to Week 24 (Prior to Rescue) in Fasting Plasma Glucose-3.25 ± 0.112-1.86 ± 0.111-2.94 ± 0.113
Statistical analysis
  • Saxagliptin + Metformin vs Saxagliptin + Placebo · ANCOVA · p = <0.001 · Mean difference (net): -1.39 · 95% CI -1.70 to -1.08
  • Saxagliptin + Metformin vs Metformin + Placebo · ANCOVA · p = 0.046 · Mean difference (net): -0.32 · 95% CI -0.63 to 0.00
SecondaryChange From Baseline to Week 24 (Prior to Rescue) in Area Under the Curve From 0-180 Minutes for Postprandial Glucose Response to a Meal Tolerance Test

To evaluate the efficacy of the combination therapy (saxagliptin + metformin) when compared to placebo + metformin and placebo + saxagliptin with respect to change in 180-minute postprandial glucose response to a meal tolerance test at the end of 24 weeks of double-blinded treatment.

Time frame:
Baseline to Week 24 prior to rescue
Reported as:
Least squares mean · mmol*min/L
Change From Baseline to Week 24 (Prior to Rescue) in Area Under the Curve From 0-180 Minutes for Postprandial Glucose Response to a Meal Tolerance Test
mmol*min/LSaxagliptin + MetforminSaxagliptin + PlaceboMetformin + Placebo
Change From Baseline to Week 24 (Prior to Rescue) in Area Under the Curve From 0-180 Minutes for Postprandial Glucose Response to a Meal Tolerance Test-1027.8 ± 36.22-611.9 ± 36.69-858.5 ± 37.36
Statistical analysis
  • Saxagliptin + Metformin vs Saxagliptin + Placebo · ANCOVA · p = <0.001 · Mean difference (net): -416.0 · 95% CI -517.3 to -314.6
  • Saxagliptin + Metformin vs Metformin + Placebo · ANCOVA · p = 0.001 · Mean difference (net): -169.3 · 95% CI -271.7 to -66.9
SecondaryGlycemic Response Defined as HbA1c ≤ 6.5% at Week 24

To evaluate the efficacy of the combination therapy (saxagliptin + metformin) when compared to placebo + metformin and placebo + saxagliptin with respect to the proportion of subjects achieving a therapeutic glycemic response defined as HbA1c ≤ 6.5% at the end of 24 weeks of double-blinded treatment.

Time frame:
Week 24 (prior to rescue)
Reported as:
Number · Percentage of patients
Glycemic Response Defined as HbA1c ≤ 6.5% at Week 24
Percentage of patientsSaxagliptin + MetforminSaxagliptin + PlaceboMetformin + Placebo
Glycemic Response Defined as HbA1c ≤ 6.5% at Week 2467.032.155.4
Statistical analysis
  • Saxagliptin + Metformin vs Saxagliptin + Placebo · Fisher Exact · p = <0.001 · Mean difference (net): 34.9 · 95% CI 26.0 to 43.9
  • Saxagliptin + Metformin vs Metformin + Placebo · Fisher Exact · p = 0.020 · Mean difference (net): 11.6 · 95% CI 2.3 to 20.9
SecondaryChange From Baseline to Week 24 in 120-minute Postprandial Glucose Response to a Meal Tolerance Test

To evaluate the efficacy of the combination therapy (saxagliptin + metformin) when compared to placebo + metformin and placebo + saxagliptin with respect to change in 120-minute postprandial glucose response to a meal tolerance test at the end of 24 weeks of double-blinded treatment.

Time frame:
Baseline to Week 24 prior to rescue
Reported as:
Least squares mean · mmol/L
Change From Baseline to Week 24 in 120-minute Postprandial Glucose Response to a Meal Tolerance Test
mmol/LSaxagliptin + MetforminSaxagliptin + PlaceboMetformin + Placebo
Change From Baseline to Week 24 in 120-minute Postprandial Glucose Response to a Meal Tolerance Test-7.09 ± 0.261-4.12 ± 0.262-5.95 ± 0.268
Statistical analysis
  • Saxagliptin + Metformin vs Saxagliptin + Placebo · ANCOVA · p = <0.001 · Mean difference (net): -2.97 · 95% CI -3.70 to -2.25
  • Saxagliptin + Metformin vs Metformin + Placebo · ANCOVA · p = 0.002 · Mean difference (net): -1.14 · 95% CI -1.88 to -0.41
SecondaryPatients Rescued for Failing to Achieve Pre-specified Glycemic Targets or Discontinuation for Lack of Efficacy During the 24-week Double-blind Treatment Phase

To evaluate the efficacy of the combination therapy (saxagliptin + metformin) when compared to placebo + metformin and placebo + saxagliptin with respect to the proportion of subjects requiring rescue for failing to achieve pre-specified glycemic targets or discontinuing for lack of efficacy within the 24 weeks of double-blinded treatment.

Time frame:
Baseline to Week 24
Reported as:
Number · Percentage of patients
Patients Rescued for Failing to Achieve Pre-specified Glycemic Targets or Discontinuation for Lack of Efficacy During the 24-week Double-blind Treatment Phase
Percentage of patientsSaxagliptin + MetforminSaxagliptin + PlaceboMetformin + Placebo
Patients Rescued for Failing to Achieve Pre-specified Glycemic Targets or Discontinuation for Lack of Efficacy During the 24-week Double-blind Treatment Phase1.410.31.4
Statistical analysis
  • Saxagliptin + Metformin vs Saxagliptin + Placebo · Fisher Exact · p = <0.001 · Mean difference (net): -8.9 · 95% CI -13.3 to -4.5
  • Saxagliptin + Metformin vs Metformin + Placebo · Fisher Exact · p = >0.999 · Mean difference (net): 0.0 · 95% CI -2.3 to 2.3

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
METFORMIN + PLACEBO 5MG QD—11/210 (5.2%)30/210 (14.3%)
SAXAGLIPTIN 5MG QD + METFORMIN—4/215 (1.9%)37/215 (17.2%)
SAXAGLIPTIN 5MG QD + PLACEBO—12/214 (5.6%)21/214 (9.8%)
Most frequent serious events
Showing 10 of 29
Most frequent serious events
EventMETFORMIN + PLACEBO 5MG QDSAXAGLIPTIN 5MG QD + METFORMINSAXAGLIPTIN 5MG QD + PLACEBO
Acute myocardial infarctionCardiac disorders1/2100/2150/214
GastritisGastrointestinal disorders1/2100/2150/214
Large intestine polypGastrointestinal disorders1/2100/2150/214
Pancreatic massGastrointestinal disorders1/2100/2150/214
Bile duct obstructionHepatobiliary disorders1/2100/2150/214
CholecystitisHepatobiliary disorders1/2100/2150/214
CholelithiasisHepatobiliary disorders1/2100/2150/214
Localised infectionInfections and infestations1/2100/2150/214
Plasma cell myelomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/2100/2150/214
Cerebral infarctionNervous system disorders1/2100/2151/214
Most frequent other events
Most frequent other events
EventMETFORMIN + PLACEBO 5MG QDSAXAGLIPTIN 5MG QD + METFORMINSAXAGLIPTIN 5MG QD + PLACEBO
Upper respiratory tract infectionInfections and infestations14/21015/21510/214
DiarrhoeaGastrointestinal disorders13/21014/2156/214
HyperlipidaemiaMetabolism and nutrition disorders7/21011/2156/214

Baseline characteristics

Age, Continuous
Age, Continuous(Years)METFORMIN + PLACEBO 5MG QDSAXAGLIPTIN 5MG QD + METFORMINSAXAGLIPTIN 5MG QD + PLACEBOTotal
Mean50.1 ± 11.0850.4 ± 10.7849.5 ± 10.9350.0 ± 10.92
Sex: Female, Male
Sex: Female, Male(Participants)METFORMIN + PLACEBO 5MG QDSAXAGLIPTIN 5MG QD + METFORMINSAXAGLIPTIN 5MG QD + PLACEBOTotal
Female767662214
Male134140152426
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)METFORMIN + PLACEBO 5MG QDSAXAGLIPTIN 5MG QD + METFORMINSAXAGLIPTIN 5MG QD + PLACEBOTotal
Asian210216214640
08

Study locations

17 sites
  • Research Site
    Beijing, China
  • Research Site
    Changchun, China
  • Research Site
    Chuangchun, China
  • Research Site
    Fuzhou, China
  • Research Site
    Guiyang, China
  • Research Site
    Ha'er bin, China
  • Research Site
    Hangzhou, China
  • Research Site
    Hefei, China
  • Research Site
    Jinan, China
  • Research Site
    Nanchang, China
  • Research Site
    Nanjing, China
  • Research Site
    Shanghai, China
  • Research Site
    Shijiazhuang, China
  • Research Site
    Siping, China
  • Research Site
    Tianjin, China
  • Research Site
    Wuxi, China
  • Research Site
    Yueyang, China
09

References and documents

Publications

  • Dou J, Ma J, Liu J, Wang C, Johnsson E, Yao H, Zhao J, Pan C. Efficacy and safety of saxagliptin in combination with metformin as initial therapy in Chinese patients with type 2 diabetes: Results from the START study, a multicentre, randomized, double-blind, active-controlled, phase 3 trial. Diabetes Obes Metab. 2018 Mar;20(3):590-598. doi: 10.1111/dom.13117. Epub 2017 Oct 26. PubMed 28926170 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2014, a primary completion of Aug 2016 and a completion of Aug 2016. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2018, 1 year 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 22, 2014
First posted
Oct 23, 2014
Start
Dec 2014
Primary completionActual
Aug 2016
CompletionActual
Aug 2016
Results first posted
Feb 5, 2018
Last update
Feb 5, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 5, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02273050
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Oct 23, 2014
Start date
Dec 2014
Primary completion
Aug 2016
Completion
Aug 2016
Results posted
Feb 5, 2018
Last update
Feb 5, 2018

Study contacts

Changyu Pan, Professor
principal investigator · The General Hospital of People's liberation Army

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Saxagliptin · Metformin

Start the discussion